Biosimilar Impact on Oncology Clinical Trial Design and Operations
Authors:
- 1 March 2022
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (3) , 157-160
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A Clinical Review of Biosimilars Approved in OncologyAnnals of Pharmacotherapy, 2020
- Coverage for Biosimilars vs Reference Products Among US Commercial Health PlansJAMA, 2020
- Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant SettingJAMA Network Open, 2018
- Our flawed approach to undue inducement in medical researchBioethics, 2018
- Ten years of biosimilars in Europe: development and evolution of the regulatory pathwaysDrug Design, Development and Therapy, 2017
- When Does the Amount We Pay Research Participants Become “Undue Influence”?AMA Journal of Ethics, 2015
- Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical TrialsJournal of Clinical Oncology, 2008